DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Study to Explore the Pharmacokinetics of Rilpivirine With Rifabutin in Healthy Participants

Information source: Janssen R&D Ireland
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Healthy

Intervention: Rilpivirine (Drug); Rifabutin (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Janssen R&D Ireland

Official(s) and/or principal investigator(s):
Janssen Research & Development, LLC Clinical Trial, Study Director, Affiliation: Janssen Research & Development, LLC

Summary

The purpose of this study is to explore the pharmacokinetics of different dosing regimens of rilpivirine in combination with rifabutin in healthy participants.

Clinical Details

Official title: A Phase I, Open-Label Study in Healthy Subjects, to Explore the Pharmacokinetics of Different Dosing Regimens of Rilpivirine in Combination With Rifabutin, at Steady-State

Study design: Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Pharmacokinetics of different dosing regimens of rilpivirine in combination with rifabutin, at steady-state

Secondary outcome: Number of participants with adverse events as a measure of safety and tolerability

Detailed description: This is a Phase I, open-label (the participant will know the identity of the treatment they receive), 3-period study to investigate the pharmacokinetic (what the body does to the medication) interaction of steady-state (constant concentrations in your blood resulting from a fixed dosing regimen) rilpivirine and steady-state rifabutin. Twenty healthy participants will be enrolled and will receive 3 different treatments (treatment A: rilpivirine 25 mg once daily administered daily for 11 days; treatment B: rilpivirine 50 mg once daily administered for 11 days + rifabutin 300 mg daily administered for 17 days; treatment C: rilpivirine (in a regimen to be determined based on an interim analysis of treatments A and B) administered for 11 days + rifabutin 300 mg daily administered for 17 days). All 20 participants will be randomized (the study drug is assigned by chance) to receive treatments A (10 participants) and treatment B (10 participants) and there will be a washout period of at least 21 days between treatments A and B. After all participants have completed treatments A and B, there will be an interim analysis to decide upon the dosing regimen for rilpivirine in treatment C (the rilpivirine regimen in treatment C could be either once daily or twice daily with a total daily dose of rilpivirine between 25 and 75 mg). All 20 participants will receive treatment C. Safety and tolerability will be evaluated throughout the study.

Eligibility

Minimum age: 18 Years. Maximum age: 55 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Participants should be healthy on the basis of physical examination, medical history,

vital signs, electrocardiogram, and the results of blood biochemistry and hematology tests and a urinalysis performed at screening

- Men must agree to use a highly effective method of birth control (ie, male condom

with either female intrauterine device, diaphragm, cervical cap or hormone based contraceptives by their female partner), and to not donate sperm during the study and for 3 months after receiving the last dose of study drug

- Women must be postmenopausal for at least 2 years, or be surgically sterile (have had

a total hysterectomy or bilateral oophorectomy, tubal ligation/bilateral tubal clips without reversal operation, or otherwise be incapable of becoming pregnant)

- Women must have a negative pregnancy test at screening

- Participants must be non-smoking for at least 3 months prior to screening

Exclusion Criteria:

- A positive HIV-1 or HIV-2 test at screening

- History or suspicion of alcohol or barbiturate, amphetamine, recreational or narcotic

drug use which in the Investigator's opinion would compromise subject safety and/or compliance with study procedures

- Hepatitis A, B or C infection (confirmed by hepatitis A IgM, HBsAg, or hepatitis C

virus antibody, respectively) at screening

- Currently active clinically significant gastrointestinal, cardiovascular, neurologic,

psychiatric, metabolic, endocrine, renal, hepatic, respiratory, inflammatory or infectious disease

- Any history of tuberculosis, ocular herpes, or uveitis

- Currently significant diarrhea or gastric stasis that in the Investigator's opinion

could influence drug absorption or bioavailability

Locations and Contacts

Merksem, Belgium
Additional Information

Starting date: April 2012
Last updated: March 27, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017